View allAll Photos Tagged Injection
Now that I make it sound all fancy like the CIA director do you believe me? Sucks to be seeing this shit so bad after a little break from it lately. For all the people who say they are just persisting contrails, why don't I see the planes on the days we have normal clouds? I see only the marked airliners doing their thing, usually leaving no contrail at all or a very short one that dissipates. Days like this I see unmarked planes that just happen to quit leaving a trail just as they pass the edge of the setting sun. Take a look for yourself, you can even see them turn around sometimes. I never used to believe in this stuff myself, but if you take some time to observe the skies you will see that something is not right up there!
4 vertical images Panorama (Camera Working Canon7D)
Katehaki Metro Station (Athens_2012COSTASDIAMANTISpho)
After Make Workspace PhotoShop Cs6
BMW E21 is the body designation for the first BMW 3 Series compact executive car, produced by the German automaker BMW from 1975 to 1983. This series was the immediate successor to the BMW 2002 and was superseded by the BMW E30.
Development and early history
Under the direction of its 51% percent shareholder, Herbert Quandt, BMW decided upon a replacement for their aging 2002. Without it, there was the distinct possibility of BMW leaving its core mission of building driver oriented cars, and alienating an existing customer base long enamored with the company's 2002 model.
Paul Bracq, Director of Design at BMW from 1970 to 1974, is credited with setting the design direction of the E21 3 Series, while Wilhelm Hofmeister is credited with first drawing the small forward wedge at the base of the C-pillar, a strong design trait of the first Three-series. In 1975 Claus Luthe replaced Bracq and became the owner of the project.
In July 1975, BMW’s Board of Management first presented this new model series in the Munich Olympic Stadium for public appraisal. The frontal view of the new car was dominated by the BMW trademark kidney grille standing out clearly from the radiator cover. The styling of the new car bore a resemblance to the BMW E12 5 Series.
The wedge shape of the two-door model was distinctive, extending all the way to the unusually high rear end. In response to criticism of the tail design, a black plastic trim panel between the tail lights was added.[citation needed] The car's styling was otherwise well received. Measuring 4355 millimeters (171.5 inches) in length, 1610 millimeters (63.4 inches) in width, and 1380 millimeters (54.3 inches) in height, the E21 Series continued the tradition of the New Class. With the wheelbase measuring 2563 millimeters (100.9 in), there was little body overhang in the rear-wheel-drive design. The track measured 1364 millimeters (53.7 in) at the front, and 1377 millimeters (54.2 in) at the rear.
The suspension incorporated rack and pinion steering and MacPherson strut suspension at the front, and semi-trailing arm type independent suspension at the rear. The power assisted brakes were discs on the front wheels, while the rear wheels had drum brakes. Initially, a Getrag four-speed manual was the standard transmission fitment. Five-speed overdrive Getrag gearboxes were fitted as standard in 1980, but close ratio 'sport' gearboxes were available at the car's release as an option. Alternatively, purchasers could opt for the ZF 3 HP-22 three-speed automatic transmission.
The cockpit design of the E21 marked the introduction of a new design concept, with the center console and central dashboard area angled towards the driver. This feature has become part of BMW’s interior design philosophy for many years. As a sign of passive safety, all edges and control elements within the interior were rounded off and padded.
At the E21's release, three models were available: with 316 (1.6-litre), 318 (1.8-litre) and 320 (2.0-litre) versions of the BMW M10 four-cylinder engine. To draw clear visual distinction within the new model series, the 320 models came with dual headlights, while the 315 - 316 and 318 had single round headlights.
At the end of 1975, the 320i was introduced; the engine was fitted with Bosch K Jetronic fuel injection, delivering 125 bhp (93 kW; 127 PS) on premium grade gasoline.
Ongoing evolution
The BMW M10 engine.
In the mid-1970s, BMW had invested DM 110 million in a new engine series, designated as the M60, but later renamed as M20 upon the introduction of the E30 in late 1982.
At the 1977 International Auto Show in Frankfurt, BMW unveiled its new variants of the E21, featuring the new six-cylinder M20 engines. The four-cylinder 320 model was replaced with the 320/6, featuring a two-litre version of the M20 engine. The 323i model was introduced, featuring 2.3 litres and 143 bhp (107 kW; 145 PS), empowering this car with a top speed of approximately 190 km/h (118 mph). The braking system was also upgraded, with the 323i featuring disc brakes on all wheels.
In the meantime however, a performance gap had developed between the 98 bhp (73 kW; 99 PS) 318 and the new 320/6 delivering 122 bhp (91 kW; 124 PS). For the 1979/80 model year, the four-cylinder models were upgraded: the 1.8-litre power unit was revised and entered the market as a 90 bhp (67 kW; 91 PS) carburetor engine in the 316, while addition of Bosch K Jetronic fuel injection to the 1.8-litre engine raised the 318i to 105 bhp (78 kW; 106 PS) .
Since there was now also room for a new entry-level model, the 315 powered by a 75 bhp (56 kW; 76 PS) 1.6-litre M10 engine made its appearance in 1981.
Motorsports
The Group 5 version of the BMW 320, introduced in 1977 as a replacement to the already obsolete BMW 3.0 CSL and became nicknamed as the Flying Brick in reference to the blocky bodyshape, was powered by a Formula Two engine that was tuned to 300 bhp (220 kW) by BMW Motorsport.
Other than the main factory team and McLaren who ran the IMSA operation in the US, the car was notably used by the BMW Junior Team, who had the likes of Manfred Winkelhock, Eddie Cheever, and Marc Surer as drivers. They would help to win the 1977 Deutsche Rennsport Meisterschaft and would later go into Formula One.
The car was also used to win the Macau Guia Race in 1981 and 1982.
[Text from Wikipedia]
There are many different germs and infections inside and outside of the healthcare setting. Despite the variety of viruses and bacteria, germs spread from person to person through a common series of events. Therefore, to prevent germs from infecting more people, we must break the chain of infection. No matter the germ, there are six points at which the chain can
be broken and a germ can be stopped from infecting another person. The six links include: the infectious agent, reservoir, portal of exit, mode of transmission, portal of entry, and susceptible host.
• Infectious agent is the pathogen (germ) that causes diseases
• Reservoir includes places in the environment where the pathogen lives (this includes people,
animals and insects, medical equipment, and soil and water)
• Portal of exit is the way the infectious agent leaves the reservoir (through open wounds, aerosols, and splatter of body fluids including coughing, sneezing, and saliva)
• Mode of transmission is the way the infectious agent can be passed on (through direct or indirect contact, ingestion, or inhalation)
• Portal of entry is the way the infectious agent can enter a new host (through broken skin, the respiratory tract, mucous membranes, and catheters and tubes)
• Susceptible host can be any person (the most vulnerable of whom are receiving healthcare, are immunocompromised, or have invasive medical devices including lines, devices, and airways)
The way to stop germs from spreading is by interrupting this chain at any link. Break the chain by cleaning your hands frequently, staying up to date on your vaccines (including the flu shot), covering coughs and sneezes and staying home when sick, following the rules for standard and contact isolation, using personal protective equipment the right way, cleaning and disinfecting the environment, sterilizing medical instruments and equipment, following safe injection practices, and using antibiotics wisely to prevent antibiotic resistance.
For other ways to protect patients, visit
It takes a chain reaction of events for infections to spread to others. The way to stop germs from spreading is by interrupting the chain. When you go into a hospital or other healthcare setting to receive care, you become vulnerable to catching infections. But the good news is that patients, their families, and visitors can take steps to prevent infections by simply knowing the top infection prevention basics!
Are you a healthcare professional? Learn how you can break the chain of infection in healthcare settings.
The best way to stay healthy while visiting the hospital is to speak up for your care. Don’t be shy. After all, we’re talking about your health. Your doctors, your nurses, and other members of your care team want you to have a voice in your care.
So ask questions, voice concerns, and make sure you’re comfortable with the care you are getting while in the hospital or other healthcare facility.
Keeping your hands clean is the number one way to prevent the spread of infection. Clean your hands after using the bathroom; after sneezing, blowing your nose, or coughing; before eating; when visiting someone who is sick; or whenever your hands are dirty.
Make sure that everyone around you, including your healthcare providers and your visitors, do too. Did you see them clean their hands? If not, it’s okay to ask them to clean their hands!
Ask about safe injection practices. Safe injection practices are steps that your healthcare providers should follow when they give injections. For example, not using the same needle or syringe on more than one patient.
Remember: One needle, one syringe, only one time.
Ask to have your room or equipment cleaned. Keeping healthcare facilities clean is extremely important. It’s very easy for germs to be passed from the surfaces to the hands and to other people.
So speak up and ask to have your room or equipment cleaned if they appear dirty or dusty.
Ask questions about the medications that are prescribed to you. Know what they are for, how to take them, how long you should take them, and how often you should take them. If you are taking antibiotics, take them exactly as prescribed, even if you start to feel better.
Using antibiotics the wrong way can cause bacteria to grow into superbugs.
Ask about vaccines you need to stay healthy. The majority of Americans who die each year from vaccine-preventable diseases are adults. Vaccines are a very effective way to prevent the suffering (and costs) associated with vaccine-preventable infections.
Vaccines are among the safest medical products available. The potential risks associated with the diseases these vaccines prevent are much greater than the potential risks associated with the vaccines themselves.
Know about infection preventionists. These germ sleuths work every day to protect you. Your safety is their #1 priority. They strive to keep you, visitors, volunteers, employees, and healthcare providers safe from infection.
Infection preventionists partner with your healthcare team to make sure everyone is doing the right things to keep you safe from healthcare-associated infections.
Become familiar with healthcare-associated infections. Healthcare-associated infections (HAIs) are infections that patients can get while receiving treatment for medical or surgical conditions. No matter where you are—in a hospital, a long-term care facility, outpatient surgery center, dialysis center, doctor’s office, or elsewhere—you are at risk for infections.
These kinds of infections are often preventable.
professionals.site.apic.org/infection-prevention-basics/b...
Evidence always plays a major role in devising a strategy for any global health crisis – it becomes even more important when the circumstances of that crisis continuously evolve. With the total count of Coronavirus patients exceeding 885,000 across more than 170 countries, it is clear that COVID-19 is a once-in-a-lifetime pandemic and a crisis of unprecedented magnitude.Italy and Spain now have over 100,000 confirmed cases of the virus, while the US will soon pass the 200,000 mark. The lesson from these developments is clear: we must abandon the assumptions that COVID-19 will be contained without drastic public health interventions. On 16 March, researchers from Imperial College of London announced a searing report on the impact of an uncontrolled pandemic, that describes the cost of inaction: approximately 510,000 deaths in the UK and 2.2 million in the US. The report highlighted that infections would peak by the middle of June and, without effective policies in place, could lead to as many as 55,000 deaths on the worst day. This scenario is corroborated by emerging evidence suggesting that younger adults, who were previously thought to be less affected – are also prone to developing severe forms of the coronavirus infection. Upon publication of the report, the UK government changed its previous policy of “building herd immunity” and the US reinforced its approach to adopt stricter measures towards containing the spread of the infection.While the numbers in the report are sobering, it does provide guidance on how to develop a global health strategy for containing COVID-19. To be successful, all major countries around the world must act now.
The report described two major approaches available for containing COVID-19. One is mitigation: slowing down the spread of the epidemic but not interrupting the transmission completely, while ensuring the healthcare needs for those who are at risk of developing serious forms of the infection are met. This approach, which includes “social distancing” along with isolation and quarantining of cases, is unlikely to contain the pandemic and may result in the death of thousands of patients while severely burdening health systems, especially available intensive care units. As such, the researchers recommend the second approach, suppression, as more optimal. Suppression refers to a reversal of epidemic spread by reducing the infectivity of the coronavirus and continued maintenance of this approach for up to 18 months. A reversal of spread can be achieved by the implementation of non-pharmaceutical interventions (NPI). These include strict lockdown measures – social distancing in entire populations, the closure of schools and community spaces – and extending these measures until vaccines can be developed. Infectivity of COVID-19 is determined by its reproduction number, or R0 (pronounced R naught), which current epidemiological estimates suggest lies between 1.5 to 3. This means that every COVID-19 patient can infect up to three other people on average. The suppression strategy will require the elimination of human-to-human transmission by lowering the R0 to less than one, which is postulated to halt the spread of the infection. Mitigation strategies, the researchers observe, are unlikely to reduce R0 to less than one. To achieve these metrics, the first step would be to test as many individuals as possible even the ones who may not exhibit symptoms. This is important because coronavirus infection has a longer incubation period of 1-14 days (compared to 1-4 days in flu) and emerging evidence suggests that people with mild or no symptoms may be responsible for the rapid spread of the infection. This approach was also underscored by the Director-General of the World Health Organization), Dr Tedros Ghebreyesus, who highlighted the importance of “breaking the chains of transmission”. This identification of infected individuals by rapid and reliable testing will be crucial to building an effective approach to impede the spread of the infection. The next critical step will be case isolation and voluntary home quarantines. These NPIs should be supplemented by strict social distancing with people maintaining almost six feet of distance along with the closure of schools, universities, bars, and other areas of social gatherings. This is especially important because recent investigation suggests that coronavirus is viable in aerosols for hours and on surfaces for days. The suppression strategy will also ensure that healthcare systems are not overburdened and capacity for critical care is preserved – a practice that has come to be known as “flattening the curve”. Failure to suppress the transmission of infection in countries like Italy has been responsible for the decimation of its healthcare systems leading to thousands of deaths. The implementation of these suppression strategies is also the reason that countries in Asia, such as Singapore, Hong Kong SAR and Taiwan, China, have succeeded in maintaining low case counts of COVID-19. Learning from the experiences of the Severe Acute Respiratory Syndrome (SARS) epidemic of 2003 and swine flu of 2009, these countries instituted strict travel controls and rapid screening and contact tracing of infected individuals. To develop resilient response systems that can halt the transmission, these countries also escalated the production of tests for COVID-19 soon after the genetic sequence of the virus became available. Singapore even enacted mandatory quarantines with criminal penalties for violators. Although some experts have highlighted the limited applicability of complete lockdown measures in developing economies, such countries can still benefit from implementing strict mitigation strategies.With a case fatality rate of up to 3.4% and up to 60% of the global population at risk, many of these measures may seem drastic, but they are also necessary to halt the transmission of this deadly pathogen. It may even seem an overreaction to an epidemic that is not well understood and where comprehensive data is missing. However, given the trajectory of the infection in Italy and the rapid collapse of its entire health system, it is prudent to exercise extreme caution to prevent other countries from trailing that path. In moments of extreme uncertainty, the judgement of leaders is as important as evidence. To combat the pandemic of COVID-19, we will need to sacrifice short-term comforts for long-term gains. More than evidence, this will require courage on the part of national leaders; their next step will become a part of their legacy.
www.weforum.org/agenda/2020/04/covid-19-containment-suppr...
Red 1987 Ford Capri Injection - E90 BSK - seen at the annual Stirling and District Classic Car Club Show, May 2014. Any extra information on the car, its history or any work done on it will be gratefully received.
Spotted this rare to see Citroen SM parked on the street, it has a 2.7Litre Maserati electronic fuel injected V6 engine
..Can't seem to resist photographing these American trucks.. Loved the colour of this one, hope everyone is ok..:-)
Ivy is a kind of easy injection, bright red veins of autumn; a winding creature, tentacled around what it touches. I think I believe in nothing so much as sinkhole stories, the kind that appear out of ordinary forests, like a cave or canyon calling. They are ones that make you disappear for hours, winding around the labyrinths and caverns, trying to figure out the maze of memories. Things are no longer right in these walls, floors collapsed and construction tenuous. I rarely go inside these days, and soon, won't even be able. This place is no time capsule, though it seemed like one at first glance. All the suggestion of everything unchanging is an illusion, missing the obvious fact that much has changed already. Ivy knows nothing but up and at 'em, everything equally climbing, don't care what's coming down. Bound by ropes or vines, all that reinforcement doing nothing to stop the implosion. It will happen in silence when no one is looking.
October 16, 2021
Annapolis County, Nova Scotia
facebook | instagram | tumblr | youtube | etsy
You can support my work
get things in the mail
and see everything
first on Patreon
The Peugeot 505 is a large family car produced from 1979 to 1992 in France. It was also built in Argentina, China, Thailand, Indonesia and Nigeria. It was Peugeot's last rear-wheel drive car. Between 1979 and 1999 1,351,254 cars were built, of which 1,116,868 sedans. This one was imported in NL on August 28, 2020.
My son was diagnosed with Type 1 diabetes about 1 year ago. I thought that his insulin would be an unusual subject
Car: Ford Capri 2.8 Injection Special.
Engine: 2792cc V6.
Power: 160 BHP.
Year of manufacture: 1985.
Date of first registration in the UK: 2nd August 1985.
Place of registration: Manchester.
Date of last MOT: 26th June 2023.
Mileage at last MOT: 99,248.
Date of last V5 issued: 21st December 2023.
Date taken: 1st June 2024.
Ford Capri Injection
B210 PLC is a Black 1985 Ford Capri Injection with a numberplate first registered in London NW in 1984. This Hatchback was first used on the road on Tuesday 23rd April 1985.
11/365
Decided to go through and get some inspiration from some of my favorite shots from Flickr today. I guess in keeping with my recent water theme, I decided to see if I could recreate, to some extent, a shot I saw a while back by Flickr member Onigun (if you haven't seen his photostream, then you'll be in for a treat with the variety that he has). For the longest time I was trying to figure out how to do it, and then today for some reason it clicked (pun sort of intended -- sorry couldn't help it). It's not quite a perfect replica, but it is inspired by what he did. All I will say it I tried a variety of things with the setup and a couple hundred tries later, I had quite a few that I liked, but I had to whittle the field down a bit.
Focusing was rather difficult at times, but I seem to have managed. I quite like this one. I had to rotate and flip it though to look the way I wanted. Added a some adjustment layers as well in CS5.
Full 365 set can be seen here.
All rights reserved. Please do not use my photo for any other use without my express permission.
Aston Martin DB6 Mk.II (1965-71) Engine 3950cc S6 DOC Production 1753
Registration Number TBM 353 J (Bedfordshire)
ASTON MARTIN SET
www.flickr.com/photos/45676495@N05/sets/72157623759800132...
Introduced at the 1965 London Motor Show, the DB6 was the first car introduced following the companies relocation from Feltham to Newport Pagnall.
Designed to be more aerodynamic than the earlier DB 5, which it resembles with the most noticeable differences being its wheelbase, side profile, split front and rear bumpers and rear panels incorporating the Kammback tail rear end. The tail, combined with the relocated rear-axle and the 3.75-inch (95 mm) lengthened wheelbase, provide more stability at high speed.
The option included the Vantage engine of 325bhp, limited slip differential, automatic and power steering (available from 1967)
The DB6 was updated as the DB6 Mk.II for the 21st August 1969 identified by distinct flares on front and rear wheel arches and wider tyres on 1/2" wider wheels. Available as an optional extra for the Mark II was AE Brico electronic fuel-injection combined with the higher compression ratio cylinder head. The Mark II edition shared many parts with the then-new DBS.
Many thanks for a fantabulous
49,842,860 views
Shot 23.04.2016 Shot at VSCC Spring Start Meeting, Silverstone REF 115-314